Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

6

Revenue 2017

Remicade

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Remicade was produced by Johnson & Johnson, Mitsubishi Tanabe Pharma and Merck & Co..

J&J files would-be prostate cancer blockbuster in US

J&J files would-be prostate cancer blockbuster in US up and the threat of biosimilar competition to big-selling biologic drugs such as Remicade (infliximab) is becoming ‘more measured’.

Samsung deal with Takeda looks beyond biosimilars

Samsung deal with Takeda looks beyond biosimilars Samsung Bioepis has already been granted approvals for biosimilars of Amgen's Enbrel (etanercept), Johnson &Johnson's Remicade (infliximab) and Sanofi's Lantus (insulin glargine), and has filed for versions of

Merck & Co's Remicade biosimilar undercuts its US rivals

Merck & Co's Remicade biosimilar undercuts its US rivals Pfizer and Celltrion's Inflectra (infliximab-dyyb) biosimilar was priced at a 15% discount to Remicade's $30, 000-a-year price tag. ... alleging patent infringement by the biosimilars, claiming it has IP protecting Remicade out to 2027, and filed a

Biosimilars eat into J&J's Remicade sales

Biosimilars eat into J&J's Remicade sales The group's prescription drug division saw revenues fall 0.2% to $8.6bn, with big-selling immunotherapy Remicade (infliximab) contracting 14% to $1.53bn thanks to the onset of biosimilar ... Currently only Inflectra is available in the US market - which

Standing out in a crowd

Standing out in a crowd It found that swapping from Remicade to a biosimilar version made by Celltrion posed no problems for patients, regardless of the disease for which they were taking the drug. ... patients that could have been switched from Remicade to Celltrion’s

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

OPEN Health reflections on the World Orphan Drug Congress in Barcelona
Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications...
R&D protocol amendments
Rethinking trials: the pros and cons of protocol amendments
Protocol amendments occur often and can be beneficial, but the steps involved can be complex...
Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...

Infographics